Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Transgene and BioInvent to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting

20201015 – BT-001_SITC poster EN

Published 15 October 2020
Categorized as 2020, BT-001, Press release

Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers

20201006 Transgene_NEC_BostonGene_Press_Release_final

Published 6 October 2020
Categorized as 2020, Myvac, Press release, TG4050

Positive clinical results for TG4001 and TG6002 and financial visibility secured until 2022

20200916 Results H1 2020 EN

Published 16 September 2020
Categorized as 2020, Press release

Transgene Announces Upcoming Investor Meetings

20200909 Next investor events

Published 9 September 2020
Categorized as 2020, Press release

Positive initial data from a Phase 1 trial with Transgene’s oncolytic virus TG6002

20200908 Transgene TG6002 Phase 1 EN

Published 8 September 2020
Categorized as -others, 2020, Invir.IO, Press release, TG6002

Transgene Receives $22.2 million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals

20200804 Transgene – Partial sale Tasly Shares EN

Published 4 August 2020
Categorized as 2020, Press release

Transgene Reports Results from Clinical Study of TG4001 in Combination with Avelumab in Advanced HPV-Positive Cancers

CP TG4001+avelumab EN – Vdef-

Published 22 July 2020
Categorized as 2020, Press release, TG4001, TG4001

Transgene and Hypertrust Patient Data Care announce successful go-live of the world’s first blockchain solution for clinical trials of personalized healthcare

20200709 PR Hypertrust Transgene EN

Published 9 July 2020
Categorized as 2020, Myvac, Press release, TG4050

Transgene’s and BioInvent’s BT-001 achieves outstanding tumor cure rates in preclinical models

20200622b – BT-001_AACR poster EN

Published 22 June 2020
Categorized as 2020, BT-001, Invir.IO, Press release

Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020

20200622a – Transgene PR AACR 3 posters

Published 22 June 2020
Categorized as 2020, BT-001, Invir.IO, Myvac, Press release

Posts pagination

Newer posts Page 1 … Page 18 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu